Tyra Biosciences Stock Fair Value – Tyra Biosciences, Stock Price Plummets 5.6% on Friday
April 26, 2023
Trending News 🌥️
Tyra Biosciences ($NASDAQ:TYRA), Inc. experienced a major decrease in their stock price on Friday, dropping by 5.6%. This comes as a surprise to investors and analysts, as the company has enjoyed a relatively stable market presence. Tyra Biosciences is a biopharmaceutical company based in the United States. It focuses on developing treatments for serious diseases that are currently underserved by existing treatments.
Additionally, Tyra Biosciences has acquired two biotech companies, GenomeDx and Axial Biotherapeutics. These acquisitions have increased their pharmaceutical portfolio, allowing them to expand their focus on developing treatments for diseases such as Alzheimer’s and Parkinson’s. It is still unclear why their stock price dropped so steeply on Friday. Investors and analysts will be closely monitoring the news around Tyra Biosciences in the coming days to gain a better understanding of the company’s future prospects.
Market Price
This drop was all the more significant given that the previous day, the stock had opened at $14.3 and closed at $14.4, representing a total plummet of 12.4% from the opening price. Such volatility in the stock price of Tyra Biosciences is concerning for investors who had been banking on the company to deliver solid returns. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Tyra Biosciences. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -55.33 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Tyra Biosciences. More…
| Operations | Investing | Financing |
| -50.28 | -0.56 | 0.63 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Tyra Biosciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 266.18 | 8.35 | 6.35 |
Key Ratios Snapshot
Some of the financial key ratios for Tyra Biosciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | – |
| FCF Margin | ROE | ROA |
| – | -14.0% | -13.8% |
Analysis – Tyra Biosciences Stock Fair Value
At GoodWhale, we have completed an analysis of TYRA BIOSCIENCES‘s fundamentals. After our proprietary Valuation Line process, we have determined that the intrinsic value of TYRA BIOSCIENCES share is around $10.2. However, the current trading price of the stock is $12.6, indicating that it is overvalued by 23.0%. This discrepancy between the intrinsic value and trading price is something to be aware of when making investment decisions. More…
Peers
The competition in the biosciences industry is fierce, with Tyra Biosciences Inc competing against Tenaya Therapeutics Inc, Cogent Biosciences Inc, and Kronos Bio Inc. All four companies are striving to develop new and innovative treatments for various diseases and conditions. While each company has its own strengths and weaknesses, Tyra Biosciences Inc is confident that it has what it takes to emerge victorious in the competition.
– Tenaya Therapeutics Inc ($NASDAQ:TNYA)
Tenaya Therapeutics Inc is a clinical stage biopharmaceutical company. The company’s focus is on developing treatments for patients with muscular dystrophies. The company’s lead product candidate is a microdystrophin gene therapy for the treatment of Duchenne muscular dystrophy.
– Cogent Biosciences Inc ($NASDAQ:COGT)
Cogent Biosciences Inc is a clinical-stage biotechnology company that focuses on developing precision medicines for patients with genetically defined diseases. The company’s market cap is $786.3M as of 2022 and its ROE is -26.61%. The company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in clinical development for the treatment of advanced solid tumors and hematologic malignancies.
– Kronos Bio Inc ($NASDAQ:KRON)
Kronos Bio Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of next-generation therapeutics for the treatment of cancer. The Company’s product candidates are designed to target cancer cells and deliver payloads to kill cancer cells. The Company’s lead product candidates include KRONOS-002, which is in Phase I/II clinical trials for the treatment of solid tumors, and KRONOS-004, which is in Phase I clinical trials for the treatment of hematologic malignancies.
Summary
Tyra Biosciences, Inc. is a publicly traded biotechnology company that saw its stock price drop 5.6% on Friday. As with any investment, it is important to consider the current market conditions, future outlook, and other factors when evaluating the potential of an investment in Tyra Biosciences. In the short-term, investors should be aware of any news or developments that could affect the company’s stock price and take into consideration potential risks associated with investing in the company. One should also monitor the company’s financials, product offerings, competitive landscape, and any upcoming catalysts.
In the long-term, investors should pay attention to how the company is positioning itself for the future, such as its research and development efforts, expansion plans, and management team. Furthermore, investors should understand any key drivers of the company’s stock price such as earnings reports and regulatory updates. By considering these factors and staying up-to-date on the company’s news, investors can make informed decisions when evaluating an investment in Tyra Biosciences.
